1. Home
  2. SEM vs SNDX Comparison

SEM vs SNDX Comparison

Compare SEM & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Select Medical Holdings Corporation

SEM

Select Medical Holdings Corporation

HOLD

Current Price

$16.30

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$23.85

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SEM
SNDX
Founded
1996
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Hospital/Nursing Management
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.8B
IPO Year
2008
2014

Fundamental Metrics

Financial Performance
Metric
SEM
SNDX
Price
$16.30
$23.85
Analyst Decision
Buy
Strong Buy
Analyst Count
4
13
Target Price
$15.17
$37.92
AVG Volume (30 Days)
3.2M
1.3M
Earning Date
04-30-2026
05-04-2026
Dividend Yield
1.53%
N/A
EPS Growth
N/A
11.56
EPS
1.16
N/A
Revenue
N/A
$172,352,000.00
Revenue This Year
$5.45
$107.40
Revenue Next Year
$4.78
$43.28
P/E Ratio
$14.04
N/A
Revenue Growth
N/A
627.84
52 Week Low
$11.65
$8.59
52 Week High
$18.61
$25.59

Technical Indicators

Market Signals
Indicator
SEM
SNDX
Relative Strength Index (RSI) 65.29 56.73
Support Level $16.20 $19.46
Resistance Level $16.59 $25.38
Average True Range (ATR) 0.03 1.12
MACD -0.02 -0.15
Stochastic Oscillator 70.00 48.90

Price Performance

Historical Comparison
SEM
SNDX

About SEM Select Medical Holdings Corporation

Select Medical Holdings Corp is a healthcare company that operates through three segments: critical illness recovery hospitals, rehabilitation hospitals, and outpatient rehabilitation clinics. Critical illness recovery hospitals which derives maximum revenue consists of hospitals designed to serve the needs of patients recovering from critical illnesses, often with complex medical needs. The rehabilitation hospital segment consists of hospitals designed to serve patients that require intensive physical rehabilitation care. Patients are typically admitted to critical illness recovery hospitals and rehabilitation hospitals from general acute care hospitals. The outpatient rehabilitation segment consists of clinics that provide physical, occupational, and speech rehabilitation services.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: